Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivos Therapeutics, Inc. (NASDAQ: VVOS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on obstructive sleep apnea (OSA) and related sleep-disordered breathing conditions, Vivos uses its SEC reports to describe its business, device portfolio, acquisitions, financing activities and governance matters.
Through periodic reports such as Forms 10-K and 10-Q, investors can review detailed discussions of Vivos’ operations, including its Complete Airway Repositioning and/or Expansion (CARE) devices, DNA appliance, Vivos Guides, VidaSleep oral appliance and related clinical and commercial initiatives. These filings also explain the company’s strategy of acquiring or affiliating with sleep centers, such as The Sleep Center of Nevada, and its revised OSA provider management model that uses jointly owned management entities.
Current reports on Form 8-K and amendments (8-K/A) highlight specific material events, including the completion of acquisitions, integration updates for sleep centers, clinical data announcements, changes to at-the-market offering programs, and the scheduling or results of stockholder meetings. Proxy statements on Form DEF 14A provide additional detail on board composition, equity incentive plans and matters submitted to stockholders for approval.
On Stock Titan, these VVOS filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key sections, such as risk factor updates, acquisition terms, and descriptions of new management or affiliation agreements. Users can also monitor items like late-filing notifications on Form 12b-25 and other compliance-related submissions. Together, the filings and AI analysis offer a structured view of how Vivos reports its evolving sleep apnea device business and sleep center operations to regulators and investors.
Vivos Therapeutics, Inc. entered a warrant inducement agreement with an institutional holder, leading to the cash exercise in full of three existing warrant series at a reduced exercise price of $2.34 per share, generating approximately $4.6 million in gross proceeds. In return, Vivos issued new Inducement Warrants: a five-year Series A and a 24‑month Series B, each to purchase up to 1,982,356 shares of common stock at an exercise price of $2.09 per share, for a total of 3,964,712 underlying shares. The company plans to use the net proceeds for working capital and general corporate purposes and must file a resale registration statement for the Inducement Warrant Shares by February 14, 2026. H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee, a 1.0% management fee, expense reimbursement, and warrants to purchase 138,765 shares at an exercise price of $2.925 per share.
Vivos Therapeutics, Inc. entered into an unsecured convertible promissory note with V-Co Investors 3 LLC for a maximum principal amount of up to $5,500,000. V-Co, an affiliate of an existing private equity investor and advisor, has already funded $900,000 under the note to provide advance funding ahead of a proposed equity financing of up to $5,500,000 that is expected to close by February 16, 2026, the Outside Date.
The maximum principal includes a 10% original issuance discount as a financing fee to V-Co. The note carries no interest unless an event of default occurs, in which case interest accrues at 15% per year. If the equity financing occurs before the Outside Date, all principal automatically converts, dollar-for-dollar, into the same equity issued in that financing; after the Outside Date, the company may repay outstanding principal and any accrued interest without penalty. The note was issued in a private placement relying on a Section 4(a)(2) exemption and is not registered under securities laws.
Vivos Therapeutics is registering 1,982,356 shares of common stock for resale by a single institutional holder, Armistice Capital, issuable upon exercise of three previously issued warrants from January 2023, November 2023 and February 2024. Vivos will not sell any shares in this offering and will not receive proceeds from resale, but could receive up to approximately $8,489,485 if the warrants are exercised for cash. As of January 12, 2026, 9,437,788 shares of common stock were outstanding. The company discloses significant additional outstanding warrants, notes that large future sales could pressure its share price and highlight risks of dilution, financing needs and stock price volatility as it pursues a new sleep-center–focused growth model.
Vivos Therapeutics, Inc. reported that it issued a press release announcing the grand opening of its latest sleep testing and treatment center near Detroit, in Auburn Hills, Michigan. The full text of the press release, dated December 16, 2025, is included as Exhibit 99.1 to the report.
Vivos Therapeutics, Inc. filed a Form 8-K to report that it released its financial results for the third quarter ended September 30, 2025. On November 19, 2025, the company issued a press release detailing these results, which is furnished as Exhibit 99.1 to the report and incorporated by reference. The company notes that this information, including Exhibit 99.1, is being furnished rather than filed, which limits certain liability and incorporation implications under securities laws.
Vivos Therapeutics, Inc. reported sharply higher revenue but widening losses for the quarter ended September 30, 2025, while highlighting substantial doubt about its ability to continue as a going concern. Quarterly revenue rose to $6.8 million from $3.9 million a year earlier, driven mainly by growth in service revenue such as sleep testing, treatment centers and billing services. For the nine months, revenue increased to $13.6 million from $11.3 million.
Despite this growth, the company posted a net loss of $5.4 million for the quarter and $14.3 million for the nine months, with higher general and administrative costs and depreciation tied to its expanding operations. Cash and cash equivalents were $3.1 million at September 30, 2025, versus total liabilities of $23.1 million, and stockholders’ equity fell to $2.5 million from $8.0 million at year-end 2024.
Vivos completed an $8.7 million acquisition of The Sleep Center of Nevada, funded partly by an $8.3 million senior secured note and new equity, adding goodwill and intangible assets and expanding its new sleep-center based distribution model. Management notes ongoing operating cash burn of $11.5 million year-to-date and states that existing cash will not fund operations for the next 12 months without additional financing.
Vivos Therapeutics (VVOS) filed a late notice for its Q3 2025 Form 10‑Q, citing the need for additional time to review and consolidate interim financial statements from its newly acquired subsidiary, The Sleep Center of Nevada (SCN), acquired on June 10, 2025. The company expects to file within the five‑day extension permitted under Rule 12b‑25.
Vivos anticipates that revenue increased by over 50% for the three months ended September 30, 2025 versus the prior‑year period, driven primarily by higher sales of Vivos products and services originating from SCN. The company also expects Sales, General and Administrative expenses to rise by over 50%, reflecting salaries, rent and other SCN operating costs, and therefore anticipates a higher net loss year over year. These figures remain under review and may change when the Form 10‑Q is filed.
Vivos Therapeutics reported results from its 2025 annual meeting. Stockholders elected R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson to one-year board terms. An amendment to the 2024 Omnibus Equity Incentive Plan was approved with 2,453,436 shares for, 516,368 against and 2,275 abstaining. Baker Tilly US, LLP was ratified as independent auditor with 4,861,139 shares for, 102,827 against and 4,762 abstaining.
Voting eligibility totaled 7,504,807 shares outstanding as of September 8, 2025, with a quorum of approximately 4,968,728 shares represented.
Vivos Therapeutics filed a prospectus supplement updating its at-the-market program under its Form S-3. The company may offer and sell common stock with an aggregate offering price of up to $3,583,686 from time to time through H.C. Wainwright & Co., as sales agent, pursuant to General Instruction I.B.6 of Form S-3.
This update reflects current I.B.6 capacity and excludes approximately $4,605,773 of shares previously sold under the prior prospectus. The public float was approximately $35,068,378, calculated from 7,477,266 non‑affiliate shares at $4.69 per share as of August 26, 2025. Over the past 12 months, the company sold securities with an aggregate market value of approximately $8,105,774 under I.B.6. VVOS last traded at $2.97 on October 23, 2025.
Vivos Therapeutics (VVOS) reported that on October 24, 2025 it filed a prospectus supplement to increase the aggregate offering price of shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., dated February 14, 2025. This update expands the capacity available for potential future issuances of common stock through the ATM program after effectiveness as permitted by the prospectus supplement.
The company also filed a legal opinion from Ellenoff Grossman & Schole LLP as Exhibit 5.1, with the related consent included in the same exhibit. VVOS’s common stock trades on The NASDAQ Stock Market LLC.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
